Micafungin (IV) [PEDS]

Usual Dose & Administration

Neonates: (max 150 mg/dose)

10 mg/kg/dose IV q24h

< 4 months: (max 150 mg/dose)

4 mg/kg/dose IV q24h (higher doses may be indicated for severe disease or refractory infection)

> 4 months (max 150 mg/dose)

2 mg/kg/dose IV q24h

Prophylaxis in hematologic malignancy or transplant (max 150 mg/dose)

1 to 3 mg/kg/dose IV q24h

Adjustment of Dose & Administration

Renal Adjustment

No dose adjustment recommended.

Hepatic Adjustment

No dose adjustment recommended.

Drug-Specific Information

Dilute < 1.5 mg/mL NS

Infuse over 1 hour

Protect from light

No significant CNS or urinary penetration

Ref: Scott, LJ. Micafungin: A Review in the Prophylaxis and Treatment of Invasive Candida Infections in Pediatric Patients. Pediatr Drugs. 2017;19:81-90.

Restricted Use

See: DUH Broad Spectrum Anti-infective Prophylaxis Guidelines for High Risk Pediatric Hematology-Oncology Patients [PEDS]

General Notes

1. Up-to-date cost information, click here 
2. IV antimicrobials outpatient (OPAT) dosing, click here
3. Obesity dosing weight recommendations here
4. Helpful drug-drug interaction check website here 
5. When dosing guidance is provided it is important to note the following:

Fixed (ie non weight-based) doses in adults are historically based on a 70 kg patient. Specific disease states or individual patients may warrant dosages that differ from the above recommendations. Since product-specific criteria for dose adjustment based on creatinine clearance exist, consult product information regarding specific recommendations for dosage adjustment based on estimated creatinine clearance.